Home > Healthcare > Pharmaceuticals > Finished Drug Form > Topical Antibiotics Market

Topical Antibiotics Market Trends

Report ID: GMI8570
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Topical Antibiotics Market Trends

The increasing microbial resistance to systemic antibiotics has enhanced the significance of topical antibiotics. As conventional antibiotic treatments lose effectiveness against resistant microbes, topical antibiotics have emerged as a valuable alternative for treating localized infections.
For instance, RMIT scientists developed Priscilicidin, a novel antibiotic with the unique ability to be rapidly re-engineered to evade resistance from harmful superbugs. This antibiotic, characterized by its small amino acid building blocks, offered adaptability to combat various forms of antimicrobial resistance. Thus, the growing innovative research reflects the increasing efforts to address antimicrobial resistance broadening antibiotic efficacy, thereby exploring opportunities for topical antibiotics in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Topical antibiotics industry size was USD 6.4 billion in 2023 and is expected to reach USD 10.4 billion by 2032, due to the increasing prevalence of bacterial infections and skin conditions globally.

The tetracycline drug class segment is set to experience 5.2% growth rate from 2024 to 2032, driven by their broad spectrum of activity against various bacterial infections, widespread availability, and established efficacy in treating a diverse range of conditions.

North America topical antibiotics industry is projected to reach USD 4.4 billion by 2032, led by advanced healthcare infrastructure, high healthcare expenditure, and a robust regulatory framework facilitating drug approvals.

Some of the prominent topical antibiotic firms are Almirall S.A., Bausch Health Companies Inc., Bayer AG, GlaxoSmithKline plc, Johnson & Johnson Consumer Inc., and Lupin, among others.